KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC

被引：112

作者：

Schmid, P. ^{[1
]}

Cortes, J. ^{[2
]}

Dent, R. ^{[3
]}

Pusztai, L. ^{[4
]}

McArthur, H. ^{[5
]}

Kummel, S. ^{[6
]}

Bergh, J. ^{[7
]}

Denkert, C. ^{[8
]}

Park, Y. H. ^{[9
]}

Hui, R. ^{[10
]}

Harbeck, N. ^{[11
]}

Takahashi, M. ^{[12
]}

Untch, M. ^{[13
]}

Fasching, P. A. ^{[14
]}

Cardoso, F. ^{[15
]}

Ding, Y. ^{[16
]}

Tryfonidis, K. ^{[17
]}

Aktan, G. ^{[17
]}

Karantza, V. ^{[17
]}

O'Shaughnessy, J. ^{[18
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] Quiron Grp, Int Breast Canc Ctr, Vall Hebron Inst Oncol, Madrid, Spain

[3] Duke Nat Univ, Singapore Med Sch, Natl Canc Ctr Singapore, Singapore, Singapore

[4] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[5] Cedars Sinai Med Ctr, Breast Oncol, Los Angeles, CA USA

[6] Kliniken Essen Mitte, Breast Unit, Essen, Germany

[7] Karolinska Univ Hosp, Karolinska Inst & Breast Canc Ctr, Dept Oncol Pathol, Canc Theme, Solna, Sweden

[8] Philipps Univ Marburg, Univ Hosp Marburg UKGM, Inst Pathol, Marburg, Germany

[9] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[10] Univ Sydney, Westmead Hosp, Westmead Breast Canc Inst, Sydney, NSW, Australia

[11] LMU Univ Hosp, Breast Ctr, Munich, Germany

[12] Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan

[13] Helios Klinikum Berlin Buch, Breast Canc Ctr, Berlin, Germany

[14] Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany

[15] Champalimaud Clin Ctr Champalimaud Fdn, Breast Unit, Lisbon, Portugal

[16] Merck Co Inc, Biostatist, Kenilworth, NJ USA

[17] Merck Co Inc, Res Labs, Kenilworth, NJ USA

[18] Baylor Univ, Med Ctr, Texas Oncol US Oncol, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷 / 09期

关键词：

D O I：

10.1016/j.annonc.2021.06.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

VP7-2021

引用

页码：1198 / 1200

页数：3